Lachlan Hanbury Brown

Stock Analyst at William Blair

(0.31)
# 4,610
Out of 5,136 analysts
146
Total ratings
40.4%
Success rate
-6.9%
Average return

Stocks Rated by Lachlan Hanbury Brown

Harrow
Oct 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.09
Upside: -
Surrozen
Oct 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $32.32
Upside: -
Eupraxia Pharmaceuticals Inc.
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.56
Upside: -
Zevra Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.25
Upside: -
uniQure
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.88
Upside: -
Sarepta Therapeutics
Sep 28, 2026
Reiterated: Hold
Price Target: n/a
Current: $15.13
Upside: -
Ocular Therapeutix
Sep 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.01
Upside: -
ARS Pharmaceuticals
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.59
Upside: -
LENZ Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.82
Upside: -
Tarsus Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $78.68
Upside: -
Reiterated: Buy
Price Target: n/a
Current: $1.46
Upside: -
Reiterated: Buy
Price Target: n/a
Current: $29.80
Upside: -
Reiterated: Buy
Price Target: n/a
Current: $6.48
Upside: -